Page last updated: 2024-11-05

trifluperidol and Neuroleptic Malignant Syndrome

trifluperidol has been researched along with Neuroleptic Malignant Syndrome in 1 studies

Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)

Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Singh, SP1
Giridhar, C1
Avasthi, A1

Other Studies

1 other study available for trifluperidol and Neuroleptic Malignant Syndrome

ArticleYear
Neuroleptic malignant syndrome with trifluperidol.
    The British journal of psychiatry : the journal of mental science, 1989, Volume: 155

    Topics: Adult; Bromocriptine; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant Syndrome; Schizop

1989